Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C

被引:218
|
作者
Wali, M
Harrison, RF
Gow, PJ
Mutimer, D [1 ]
机构
[1] Queen Elizabeth Hosp, Liver & Hepatobiliary Unit, Birmingham B15 2TH, W Midlands, England
[2] Univ Birmingham, Dept Med, Birmingham, W Midlands, England
[3] Univ Birmingham, Dept Pathol, Birmingham, W Midlands, England
关键词
D O I
10.1136/gut.51.2.248
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and aims: Cirrhosis with liver failure due to hepatitis C virus (HCV) infection is the most common indication for liver transplantation (LT). Reinfection of the transplanted liver by HCV is inevitable, and aggressive hepatitis with accelerated progression to graft cirrhosis may be observed. Of concern, recent reports suggest that the outcome of LT for HCV may have deteriorated in recent years. Determinants of rate of progression to cirrhosis in the immunocompetent non-transplant patient are well defined, and the most powerful determinant is patient age at the time of infection. Following LT for HCV, recipient age does not affect outcome of HCV reinfection. However, the impact of donor age on graft fibrosis progression rate following LT has not been examined. Methods: We have examined post-transplant biopsies to assess histological activity, including fibrosis stage (scored 0-6 units, 6 representing established cirrhosis), and to calculate fibrosis progression rates in 101 post-transplant specimens from 56 HCV infected LT patients. Univariate and multivariate analyses examined the impact of parameters including recipient and donor age and sex on fibrosis progression rate, and on predicted time to cirrhosis. Results: For the cohort, median fibrosis progression rate was 0.78 units/year, and median interval from transplantation to development of cirrhosis was 7.7 years. In multivariate analysis, donor age (not recipient age) was a powerful determinant (p=0.02) of fibrosis progression rate. When the liver donor was younger than 40 years, median progression rate was 0.6 units/year and interval to cirrhosis was 10 ears. When the donor was aged 50 years or more, median progression rate was 2.7 units/year and interval to cirrhosis only 2.2 years. During the observation period there has been a significant increase in donor age (p=0.01) but date of transplantation per se is not a determinant of progression rate when included in multivariate analyses. Conclusions: Donor age has a major influence on graft outcome following transplantation for HCV. The changing organ donor profile will affect the long term results of LT for HCV. These observations have important implications for donor liver allocation.
引用
收藏
页码:248 / 252
页数:5
相关论文
共 50 条
  • [31] Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation
    Chopra, KB
    Demetris, AJ
    Blakolmer, K
    Dvorchik, I
    Laskus, T
    Wang, LF
    Araya, VR
    Dodson, F
    Fung, JJ
    Rakela, J
    Vargas, HE
    TRANSPLANTATION, 2003, 76 (10) : 1487 - 1491
  • [32] DONOR AGE AFFECTS RESPONSE TO ANTIVIRAL THERAPY IN PATIENTS WITH RECURRENT HEPATITIS C FOLLOWING LIVER TRANSPLANTATION
    Lilly, Leslie
    Therapondos, George
    Selzner, Nazio
    Levy, Gary A.
    Renner, Eberhard L.
    HEPATOLOGY, 2008, 48 (04) : 578A - 578A
  • [33] The influence of donor age, gender mismatch and harvesting injury on fibrosis progression rate in recurrent hepatitis C (HCV) post-liver transplantation.
    Blank, A
    Schiano, T
    Gutierrez, JA
    Gan, D
    Thung, SN
    Fiel, MI
    HEPATOLOGY, 2004, 40 (04) : 243A - 243A
  • [34] Fibrosis progression after liver transplantation in patients with recurrent hepatitis C.
    Neumann, UP
    Berg, T
    Neuhaus, P
    HEPATOLOGY, 2003, 38 (04) : 227A - 227A
  • [35] Recurrent hepatitis C after liver transplantation: Accelerated fibrosis progression.
    Honorio, Rodrigo S.
    Mello, Evandro S.
    Alves, Venancio A. F.
    Lima, Fabiana R.
    Abdala, Edson
    Bachella, Telesforo
    Figueira, Estela R. R.
    Bonazzi, Patricia R.
    Gotardo, Daniela M. M.
    Machado, Marcel C. C.
    LIVER TRANSPLANTATION, 2007, 13 (06) : S183 - S183
  • [36] Role of donor liver steatosis on immune responses to Hepatitis C, self antigens and allograft fibrosis following human liver transplantation
    Subramanian, Vijay
    Seetharam, Anil
    Tiriveedhi, Venkataswarup
    Angaswamy, Nataraju
    Anderson, Christopher
    Shenoy, Surendra
    Crippin, Jeffrey
    Chapman, William
    Mohanakumar, Thalachallour
    JOURNAL OF IMMUNOLOGY, 2011, 186
  • [37] Donor PNPLA3 rs738409 Genotype Affects Fibrosis Progression in Liver Transplantation for Hepatitis C
    Dunn, Winston
    O'Neil, Maura
    Zhao, Jie
    Wu, Chuang Hong
    Roberts, Benjamin
    Chakraborty, Shweta
    Sherman, Craig
    Weaver, Brandy
    Taylor, Ryan
    Olson, Jody
    Olyaee, Mojtaba
    Gilroy, Richard
    Schmitt, Timothy
    Wan, Yu-Jui Yvonne
    Weinman, Steven A.
    HEPATOLOGY, 2014, 59 (02) : 453 - 460
  • [38] Progression of liver fibrosis in patients with recurrent hepatitis C after orthotopic liver transplantation.
    Teixeira, R
    Papatheodoridis, GV
    Sabin, C
    Davis, S
    Dillon, AP
    Dagher, L
    Pastacaldi, S
    Davidson, B
    Rolles, K
    Patch, D
    Burroughs, AK
    HEPATOLOGY, 2000, 32 (04) : 258A - 258A
  • [39] Prolonged warm ischemic time and older donor age are predictors of rapid hepatic fibrosis after liver transplantation for hepatitis HCV
    Wali, MH
    Harrison, RF
    Mutimer, DJ
    Gow, PJ
    JOURNAL OF HEPATOLOGY, 2001, 34 : 8 - 9
  • [40] Recurrence of Hepatitis C following living donor vs. deceased donor liver transplantation
    Girgrah, N
    Lilly, L
    Chen, D
    Levy, G
    Wong, P
    Grant, D
    McGilvray, I
    Greig, P
    Adcock, L
    Smith, R
    Cattral, M
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 524 - 525